TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01218633

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: saline infused at 30ml/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1-9,36 infusion
Description: infused @ 1.2pmol/kg/min
Study: NCT02511561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201 (ciprofloxacin)
Study: NCT04145297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily. Fixed Dose 600mg POBID. Medication will be administered in 28-day cycles
Study: NCT01218633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39 at low dose
Description: infused at 30pmol/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39 at high dose
Description: infused @ 300pmol/kg/min
Study: NCT03395054

Intervention type: OTHER
Group type: OTHER
Intervention: cervical stabilization exercises
Description: cervical stabilization exercises

Intervention type: OTHER
Group type: OTHER
Intervention: conventional exercises
Description: conventional exercises
Study: NCT04282512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-rich mineral water
Description: St-Yorre, a sodium bicarbonate-rich mineral water, is a commercial mineral water that contains 4368 mg/l sodium bicarbonate. The study intends to evaluate the effect on blood pressure of the sodium bicarbonate intake due to this mineral water consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-rich mineral water
Description: St-Yorre, a sodium bicarbonate-rich mineral water, is a commercial mineral water that contains 4368 mg/l sodium bicarbonate. The study intends to evaluate the effect on blood pressure of the sodium bicarbonate intake due to this mineral water consumption.
Study: NCT00633620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test)
Description: colonoscopy withdrawal with NBI mode
Study: NCT01266941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled FF 200mcg/GW642444M 25mcg
Description: All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled FF 200mcg/GW642444M 25mcg
Description: All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
Study: NCT04598607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypidone Hydrochloride tablets
Description: 30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypidone Hydrochloride tablets
Description: 30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.
Study: NCT04541680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 MG [Ofev]
Description: Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03247699

Intervention type: OTHER
Group type: OTHER
Intervention: Basel phenotyping cocktail capsule
Description: Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Basel phenotyping cocktail individual components
Description: Oral intake of Basel phenotyping cocktail individual components and PK sampling
Study: NCT00147914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefdinir (drug)
Description: cefdinir 300mg per orally twice daily for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin/clavulanate
Description: 1000mg /62.5mg extended release per orally twice daily for 10 days
Study: NCT04112368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Transdermal Patch 0.1 mg/24 hrs
Description: Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol Transdermal Patch 0.1 mg/24 hrs
Description: Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Micronized Progesterone 200mg
Description: 100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation (200mg total per day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Micronized Progesterone 200mg
Description: 100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation (200mg total per day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactive Clear Patch
Description: Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Clear Patch
Description: Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
Study: NCT01278537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Booklet, motivational interviewing, brief advice
Study: NCT00002569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT03908242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvianolic acid A
Description: salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
Study: NCT03328052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MYnd Analytics PEER Online directed antidepressant therapy
Description: PEER Online is similar to a standard QEEG in that it uses QEEG output variables, but differs from a standard QEEG in that it references the QEEG to a normative and then symptomatic database. By comparing a given patient's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER Online can provide useful information regarding the response of neuro-physiologically similar patients to a wide number of medications. PEER Online may thus have the advantage of providing physicians with useful information as to medication outcomes before a medication regime is started. It has also been used to help select the medication that best matches the QEEG brainwave pattern, regardless of symptom clusters, currently used for diagnostic nomenclature. Patients will receive anti-depressant therapy guide by the results of the PEER Online algorithm.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional antidepressant therapy
Description: Anti-depressant therapy chosen based on physician best judgement.
Study: NCT02700685

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Description: Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Standard pharmaceutical treatment for ADHD, slow release.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment (identical capsules containing excipients only)
Study: NCT03923608

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal muscle strength Test
Description: 1RM test performed in 5 different tools (Elastic Band, Pulley, halter, digital dynamometer and isokinetic dynamometer)

Intervention type: DIAGNOSTIC_TEST
Intervention: Exhaustion test
Description: Test performed until individual exhaustion in 5 different tools (Elastic Band, Pulley, halter and isokinetic dynamometer)
Study: NCT04627883

Intervention type: OTHER
Group type: OTHER
Intervention: Inspiratory-to-expiratory (I : E) ratio of 1:2
Description: After preoxygenation and induction of anesthesia, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2 for 5 min before endotracheal intubation.

Intervention type: OTHER
Group type: OTHER
Intervention: Inspiratory-to-expiratory (I : E) ratio of 2:1
Description: After preoxygenation and induction of anesthesian, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1 for 5 min before endotracheal intubation.
Study: NCT01026415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: 600 mg/day PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 1 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: 400 mg/day PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2 mg/kg IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2 mg/kg IV every 21 days
Study: NCT01806415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenobam
Description: Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenobam
Description: Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenobam
Description: Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo or lactose 150 mg
Study: NCT03905382

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative
Description: Focus group and 1:1 telephone interviews
Study: NCT01581853

Intervention type: DRUG
Group type: OTHER
Intervention: Lopinavir/ritonavir 800 mg / 200mg
Description: Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
Study: NCT02186938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FloTrac
Study: NCT03432533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: romosozumab HCP administration with PFS
Description: 210 mg romosozumab SC QM by HCP administration with 2 PFS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: romosozumab self-administration with AI/Pen
Description: 210 mg romosozumab SC QM by self-administration with 2 AI/Pens
Study: NCT04645186

Intervention type: DEVICE
Intervention: bone graft substitute
Description: Filling bone defects in current clinical practice
Study: NCT02362633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS
Description: For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham tDCS will be delivered for 20 minutes. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
Study: NCT02300311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonivamide + nicoboxil (Finalgon cream)
Description: 2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo matching nonivamide + nicoboxil (Finalgon cream)
Description: 2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
Study: NCT01944943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: 150 mg (1 capsule) of Vismodegib per day orally in continue during 12 months
Study: NCT00816582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline
Description: A18F-FDG PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to identify the sites involved by the subject's cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging: 18F-FES PET/CT - Baseline
Description: A 18F-FES PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to determine the hormone receptor content of the sites involved by the breast cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up
Description: A 18F-FES PET/CT scan performed after three (3) monthly injections of fulvestrant to determine whether estrogen uptake is blocked by fulvestrant.
Study: NCT01653743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSJ-0011
Description: Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa \[recombinant human Chorionic Gonadotropin, r-hCG\]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (\>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of \>=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: urinary hCG (u-hCG)
Description: Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of \>=18 mm; not more than 3 follicles each with a mean diameter of \>=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alpha
Description: Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alpha
Description: Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
Study: NCT03748771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ApneaLink Air
Description: The ApneaLink Air device is indicated for use by Health Care Professionals (HCP), where it may aid in the diagnosis of sleep disordered breathing for adult patients.~ApneaLink Air records the following data: patient respiratory nasal airflow, snoring, blood oxygen saturation, pulse and respiratory effort during sleep. The device uses these recordings to produce a report for the HCP that may aid in the diagnosis of sleep disordered breathing or for further clinical investigation. The device is intended for home and hospital use under the direction of a HCP.
Study: NCT03246672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maintenance intervention
Description: Participants will receive calls at weeks 1, 2, 3, 4, 6, 8, 10, 12, and 14 that focus on satisfaction with outcomes of behavior change, self-monitoring, relapse planning, and social support.
Study: NCT00209729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: X mg/m2, IV (in the vein) on day 1 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: Day 1-14, P.O. everyday
Study: NCT03618303

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-MRI scan
Description: Patients will undergo combined Positron Emission Tomography and Magnetic Resonance Imaging prior to a planned invasive angiogram (performed as standard of care). During the angiogram procedure, an additional imaging test (optical coherence tomography) will be performed.
Study: NCT02113111

Intervention type: BEHAVIORAL
Intervention: Fasting
Description: Fasting therapy was adapted from Buchinger, including a fasting period of 7 days. After 2 prefasting days with 800kcal per day from vegetables and rice/potatoes, fasting starts with the ingestion of an oral laxative. During fasting patients receive small quantities of juice and herbal teas, and a vegetable broth for lunch, altogether no more than 350kcal per day. At the end, fasting is broken by an apple or cooked potato, and for the following 3 days nutrition returns to normocaloric diet.
Study: NCT03281343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing & Patient Navigator
Description: The specific content, structure, and implementation approach for MI-NAV will be guided by IDIs conducted during Phase 1 and Phase 2. Our initial plan is to deliver MI-NAV in two waves. The first wave will be aimed at promoting uptake of PrEP at the prison, through the use of motivational interviewing. The second wave will be aimed at linking at-risk women to community-based PrEP care upon release from incarceration, by utilizing a patient navigator approach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: SOC will consist of a pamphlet regarding PrEP during incarceration, an offer of PrEP while incarcerated, and referral to community-based PrEP care upon release.
Study: NCT03605875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-App
Description: Cambian IT Health solutions from Surrey BC developed the infrastructure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper
Description: Contains similar questions to the Web-App tool
Study: NCT01631708

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erythrocytapheresis
Description: To achieve a blinded randomised trial, apheresis treatment will be used. Those in arm 1 will have erythrocytapheresis reducing iron levels and those in arm 2 will have plasmapheresis and their iron levels will not be reduced.~An apheresis machine will be used to remove red blood cells only from the erythrocytapheresis group. Subjects will have third weekly treatments until SF levels are reduced to \~100 ug/L in accordance with current guidelines.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Plasmapheresis
Description: An apheresis machine will be used to remove blood plasma only from the plasmapheresis group. Those in arm 2 will have the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm. Those in the sham arm will be offered to have venesection at their choice of venue or to have their SF normalised by erythrocytapheresis after the initial blinded part of the study. This will be done because it will not be known for some time if there is benefit from normalisation of SF and therefore leaving people with elevated SF that may be harmful.
Study: NCT01438437

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAI
Description: Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.
Study: NCT04582045

Intervention type: DEVICE
Intervention: silver impregnated dressing
Description: comparison of Mepilex versus our standard techniques

Intervention type: DEVICE
Intervention: silver impregnated dressing
Description: comparison of Mepilex versus our standard techniques
Study: NCT02171702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study: NCT03508271

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT02744469

Intervention type: OTHER
Intervention: No intervention (observational study)

Intervention type: OTHER
Intervention: No intervention (observational study)